Analysts think NBIX stock price could increase by 21%
Sep 05, 2025, 11:26 AM
2.63%
What does NBIX do
Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
28 analysts think NBIX stock price will increase by 20.92%. The current median analyst target is $169.83 compared to a current stock price of $140.45. The lowest analysts target is $125.24 and the highest analyst target is $210.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.